Incannex Healthcare Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Incannex Healthcare Inc. (IXHL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $4.51 million for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-29.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2025-09-29
- Incannex Healthcare Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2025 was $4.51M, a 31.08% decline from fiscal 2024.
- Incannex Healthcare Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $6.54M, a 82.02% decline from fiscal 2023.
- Incannex Healthcare Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $36.41M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2025-06-30 | $4.51M 10-K · filed 2025-09-29 |
| 2024-06-30 | $6.54M 10-K · filed 2025-09-29 |
| 2023-06-30 | $36.41M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B |